<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02794168</url>
  </required_header>
  <id_info>
    <org_study_id>VAS203/III/1/04</org_study_id>
    <nct_id>NCT02794168</nct_id>
  </id_info>
  <brief_title>Efficacy of VAS203 (Ronopterin) in Patients With Moderate and Severe Traumatic Brain Injury</brief_title>
  <acronym>NOSTRA-III</acronym>
  <official_title>Efficacy of VAS203 (Ronopterin) in Patients With Moderate and Severe Traumatic Brain Injury - (NOSTRA Phase III Trial): A Confirmatory, Placebo-controlled, Randomised, Double Blind, Multi-centre Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vasopharm GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ICON plc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Vasopharm GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the efficacy of an infusion of Ronopterin (VAS203) on clinical outcome&#xD;
      in patients with moderate and severe traumatic brain injury. Half of the participants will&#xD;
      receive Ronopterin (VAS203), while the other half will receive placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Severe and moderate traumatic brain injury (TBI) constitutes a major health problem. TBI is&#xD;
      the leading cause of death and disability among young adults in developed countries, and the&#xD;
      incidence in the elderly population is increasing.&#xD;
&#xD;
      Neurological damage after TBI is caused not only by the accident itself, but evolves&#xD;
      afterwards. The posttraumatic secondary injury includes - among others - inflammation and&#xD;
      oedema formation with subsequent increase of intracranial pressure. A key molecule in these&#xD;
      processes is the gas nitric oxide, which is produced in excess during neuroinflammation.&#xD;
&#xD;
      Ronopterin (VAS203) is an inhibitor of nitric oxide synthase. Ronopterin reduces excess&#xD;
      nitric oxide production and subsequent secondary injury.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2016</start_date>
  <completion_date type="Actual">June 30, 2020</completion_date>
  <primary_completion_date type="Actual">June 30, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>extended Glasgow Outcome Scale</measure>
    <time_frame>6 months</time_frame>
    <description>clinical outcome questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life after brain injury (QOLIBRI)</measure>
    <time_frame>6 months</time_frame>
    <description>clinical outcome questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QOLIBRI overall scale</measure>
    <time_frame>6 months</time_frame>
    <description>clinical outcome questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>extended Glasgow Outcome Scale</measure>
    <time_frame>3 months</time_frame>
    <description>clinical outcome questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QOLIBRI overall scale</measure>
    <time_frame>3 months</time_frame>
    <description>clinical outcome questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Therapy Intensity Level</measure>
    <time_frame>14 days</time_frame>
    <description>Daily recording of score for therapeutic measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of decompressive craniectomies</measure>
    <time_frame>14 days</time_frame>
    <description>Number of decompressive craniotomies on both hemispheres</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse Events</measure>
    <time_frame>14 days</time_frame>
    <description>Number of adverse events related to treatment</description>
  </other_outcome>
  <other_outcome>
    <measure>Renal function</measure>
    <time_frame>14 days</time_frame>
    <description>Number of patients exhibiting acute kidney injury according Acute Kidney Injury Network criteria</description>
  </other_outcome>
  <other_outcome>
    <measure>Mortality</measure>
    <time_frame>6 Months</time_frame>
    <description>Mortality 6 months after traumatic brain injury</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">224</enrollment>
  <condition>Traumatic Brain Injury</condition>
  <arm_group>
    <arm_group_label>VAS203 (Ronopterin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous infusion of 17 mg/kg VAS203 over 48 hours, daily dose 8.5 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intravenous infusion of physiological saline over 48 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VAS203</intervention_name>
    <description>Treatment</description>
    <arm_group_label>VAS203 (Ronopterin)</arm_group_label>
    <other_name>Ronopterin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent from patient's legal guardian or legal representative or&#xD;
             deferred consent procedure, according to local requirements&#xD;
&#xD;
          2. 18 - 60 years of age, inclusive&#xD;
&#xD;
          3. Expected to survive more than 24 hours after admission&#xD;
&#xD;
          4. Traumatic Brain Injury (TBI) within the last 18 hours (infusion must not start earlier&#xD;
             than 6 hours after the injury)&#xD;
&#xD;
          5. TBI with Glasgow Coma Score (GCS) ≥ 3 requiring intracranial pressure (ICP) monitoring&#xD;
             according to the assessment of the treating physician.&#xD;
&#xD;
          6. Catheter placement (intraventricular or intraparenchymal, only) for monitoring and&#xD;
             management of increased ICP&#xD;
&#xD;
          7. Systolic blood pressure ≥ 100 mmHg&#xD;
&#xD;
          8. Females of child-bearing potential must have a negative pregnancy test&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Penetrating head injury (e.g. missile, stab wound)&#xD;
&#xD;
          2. Concurrent, but not pre-existing, spinal cord injury&#xD;
&#xD;
          3. Bilateral fixed and dilated pupil (&gt; 4 mm)&#xD;
&#xD;
          4. Cardiopulmonary resuscitation performed post injury, or extracranial injuries causing&#xD;
             continuing bleeding likely to require multiple transfusions (&gt; 4 units red blood&#xD;
             cells)&#xD;
&#xD;
          5. Coma due to an exclusive epidural hematoma (lucid interval and absence of structural&#xD;
             brain damage on CT scan)&#xD;
&#xD;
          6. Coma suspected to be primarily due to other causes than head injury (e.g. drug&#xD;
             overdose intoxication, drowning/near drowning)&#xD;
&#xD;
          7. Known or CT scan evidence of pre-existing major cerebral damage&#xD;
&#xD;
          8. Patients who cannot be monitored with regard to their recovery (eGOS-I and QOLIBRI)&#xD;
&#xD;
          9. Patients and relatives of patients who don´t understand/speak Spanish, or English, or&#xD;
             French, or German&#xD;
&#xD;
         10. Decompressive craniectomy, planned prior to randomisation&#xD;
&#xD;
         11. Polytraumatic patients with Injury Severity Score non-head &gt; 18&#xD;
&#xD;
         12. Rhabdomyolysis with Creatine Kinase &gt; 5000 IU/L&#xD;
&#xD;
         13. Injuries to ascending aorta and/or carotid arteries and vertebral arteries&#xD;
&#xD;
         14. Serum creatinine values &gt; 1.2 mg/dL (106 µmol/L) (women), or &gt; 1.5 mg/dL (133 µmol/L)&#xD;
             (men)&#xD;
&#xD;
         15. Estimated glomerular filtration rate (eGFR) &lt; 60 mL/min as calculated by Chronic&#xD;
             Kidney Disease Epidemiology Collaboration Formula&#xD;
&#xD;
         16. BMI &lt; 18.5 kg/m2 and &gt; 40 kg/m2, Body weight &gt; 110 kg&#xD;
&#xD;
         17. Any severe concomitant condition (cancer; hematologic, renal, hepatic, coronary&#xD;
             disease; major psychiatric disorder; alcohol or drug abuse), that can be ascertained&#xD;
             at admission&#xD;
&#xD;
         18. Known to have received an experimental drug within 4 weeks prior to current injury&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erich Schmutzhard, Prof. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University Innsbruck</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsklinik für Neurochirurgie</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologie und Neurochirurgie Medizinische Universität Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Allgemeine Anästhesie und Intensivmedizin AKH Wien</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Pellegrin Service de réanimation traumatologique et chirurgicale</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Gabriel Montpied</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pôle Anesthésie Réanimation Douleur Urgence</name>
      <address>
        <city>Nimes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HIA Sainte-Anne Boulevard Sainte-Anne</name>
      <address>
        <city>Toulon</city>
        <zip>83800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite Virchow-Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Berufsgenossenschaftliche Kliniken Bergmannsheil Klinik für Neurochirurgie</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allgemeines Krankenhaus Celle Neurotraumatologie</name>
      <address>
        <city>Celle</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Düsseldorf Neurochirurgische Klinik</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Neurochirurgie Universität Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Göttingen Klinik für Neurochirurgie</name>
      <address>
        <city>Göttingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Berufsgenossenschaftliche Kliniken Bergmannstrost Halle Klinik für Neurochirurgie</name>
      <address>
        <city>Halle</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf Klinik und Poliklinik für Neurochirurgie</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover Klinik für Neurochirurgie</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurochirurgische Universitätsklinik Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum des Saarlands</name>
      <address>
        <city>Homburg</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Jena Klinik und Poliklinik für Neurochirurgie</name>
      <address>
        <city>Jena</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein Klinik für Neurochirurgie</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig Klinik und Poliklinik für Neurochirurgie</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vall d'Hebron University Hospital Department of Neurosurgery</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario</name>
      <address>
        <city>Elche</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Son Espases University Hospital</name>
      <address>
        <city>Palma</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital Birmingham</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHS Lothian University of Edinburgh</name>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kings College Hospital London</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southampton University Hospital Division of Clinical Neurosciences</name>
      <address>
        <city>Southampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>France</country>
    <country>Germany</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Stover JF, Belli A, Boret H, Bulters D, Sahuquillo J, Schmutzhard E, Zavala E, Ungerstedt U, Schinzel R, Tegtmeier F; NOSTRA Investigators. Nitric oxide synthase inhibition with the antipterin VAS203 improves outcome in moderate and severe traumatic brain injury: a placebo-controlled randomized Phase IIa trial (NOSTRA). J Neurotrauma. 2014 Oct 1;31(19):1599-606. doi: 10.1089/neu.2014.3344. Epub 2014 Jul 28.</citation>
    <PMID>24831445</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 31, 2016</study_first_submitted>
  <study_first_submitted_qc>June 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2016</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

